Phase II study of bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Bortezomib (Primary) ; Cisplatin (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jan 2013 Planned end date changed from 1 Dec 2009 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 11 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.